Induction Therapy in Simultaneous Pancreas-Kidney Transplantation: Thymoglobulin Versus Basiliximab

Fernández-Burgos, I; Casado, María Custodia Montiel; Pérez-Daga, J.A.; Aranda-Narváez, José Manuel; Sánchez-Pérez, Belinda; León-Díaz, F.J.; Cabello-Díaz, Mercedes; Rodríguez-Burgos, D.; Marrero, Domingo Hernández; Santoyo-Santoyo, Julio

doi:10.1016/j.transproceed.2014.12.003

Cited by 19 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some single-center studies have suggested ATG use to reduce graft rejection in pancreas transplantation, in comparison with basiliximab. 44,45 As a matter of fact, most pancreatic graft recipients receive T-lymphocyte depleting induction therapy. 46 Restoration of normoglycemia by endogenously regulated insulin release as achievable with beta cell replenishment (pancreas or islet transplantation) prevents acute complications of diabetes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treating Type 1 Diabetes by Pancreas Transplant Alone: A Cohort Study on Actual Long-term (10 Years) Efficacy and Safety

et al. 2021

View full text Add to dashboard Cite

Patient and pancreas survival after PTA. Patient (upper black line) and pancreas (lower dashed line) survival over 10 y follow-up in 66 subjects with type 1 diabetic and with PTA. Pancreas survival includes grafts with optimal function and graft with good function (n: 2, passed from optimal to good function at 1 and 8 y after transplantation). Functional definition was according to Ref. 29. PTA, pancreas transplant alone.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Treating Type 1 Diabetes by Pancreas Transplant Alone: A Cohort Study on Actual Long-term (10 Years) Efficacy and Safety

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The study reported a 5‐year pancreas graft survival rate of 65.3% and a patient survival rate of 89.5% 23 . In another single‐center Spanish study of 97 patients, 5‐year pancreas graft survival was 81% 24 …”

Section: Introductionmentioning

confidence: 94%

Favorable outcomes in Hispanic recipients receiving simultaneous pancreas kidney transplantation

Budhiraja

Reddy

Heilman

et al. 2023

Clinical Transplantation

View full text Add to dashboard Cite

The objective of this study was to compare the long‐term outcomes of Hispanic versus white recipients who underwent simultaneous pancreas kidney transplantation (SPKT). This single‐center study, conducted from 2003 to 2022, had a median follow‐up of 7.5 years. The study included 91 Hispanic and 202 white SPKT recipients. The mean age (44 vs. 46 years), percentage of males (67% vs. 58%), and body mass index (BMI) (25.6 vs. 25.3 kg/m2) were similar between the Hispanic and white groups. The Hispanic group had more recipients with type 2 diabetes (38%) compared to the white group (5%, p < .001). The duration of dialysis was longer in Hispanics (640 vs. 473 days, p = .02), and fewer patients received preemptive transplants (10% vs. 29%, p < .01) compared to whites. Hospital length of stay, rates of BK Viremia, and acute rejection episodes within 1 year were similar between the groups. The estimated 5‐year kidney, pancreas, and patient survival rates were also similar between the groups, 94%, 81%, and 95% in Hispanics, compared to 90%, 79%, and 90% in whites. Increasing age and longer duration of dialysis were risk factors for death. Although Hispanic recipients had a longer duration on dialysis and fewer preemptive transplants, the survival rates were similar to those of white recipients. However, referring providers and many transplant centers continue to overlook pancreas transplants for appropriately selected patients with type 2 diabetes, particularly among minority populations. As a transplant community, it is crucial that we make efforts to comprehend and tackle these obstacles to transplantation.

show abstract

“…Some B-cell depleting therapies have been reported but used very infrequently (<0.6%), and were not be the focus of this review. All three induction therapies have acceptable rates of rejection, with multiple observational and prospective studies finding very little difference between the three [143][144][145][146][147][148][149][150][151][152][153][154][155][156].…”

Section: Immunosuppressionmentioning

confidence: 99%

Working towards an ERAS Protocol for Pancreatic Transplantation: A Narrative Review

Elango

Papalois

2021

JCM

View full text Add to dashboard Cite

Enhanced recovery after surgery (ERAS) initially started in the early 2000s as a series of protocols to improve the perioperative care of surgical patients. They aimed to increase patient satisfaction while reducing postoperative complications and postoperative length of stay. Despite these protocols being widely adopted in many fields of surgery, they are yet to be adopted in pancreatic transplantation: a high-risk surgery with often prolonged length of postoperative stay and high rate of complications. We have analysed the literature in pancreatic and transplantation surgery to identify the necessary preoperative, intra-operative and postoperative components of an ERAS pathway in pancreas transplantation.

show abstract

Induction Therapy in Simultaneous Pancreas-Kidney Transplantation: Thymoglobulin Versus Basiliximab

Cited by 19 publications

References 6 publications

Treating Type 1 Diabetes by Pancreas Transplant Alone: A Cohort Study on Actual Long-term (10 Years) Efficacy and Safety

Treating Type 1 Diabetes by Pancreas Transplant Alone: A Cohort Study on Actual Long-term (10 Years) Efficacy and Safety

Favorable outcomes in Hispanic recipients receiving simultaneous pancreas kidney transplantation

Working towards an ERAS Protocol for Pancreatic Transplantation: A Narrative Review

Contact Info

Product

Resources

About